SWOG S2209: A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance

Objective

Clinical Trial Details

Principal Investigator(s)
Xavier Andrade-Gonzalez, MD

Clinical Trial Categories

  • Multiple Myeloma
Contact
Hematology Research Coordinators at 605-322-3090
or hematologyresearch@avera.org

Location

  • Avera Cancer Institute — Mitchell
    605 N Foster St
    Mitchell, SD 57301
    Main: 605-995-5756
  • Avera Cancer Institute — Yankton
    1115 W 9th St
    Yankton, SD 57078
    Main: 605-668-8850
  • Avera Cancer Institute — Sioux Falls
    1000 E 23rd St
    Suite 340
    Sioux Falls, SD 57105
    Main: 605-322-3000
  • Avera Cancer Institute — Aberdeen
    310 S Penn St
    Suite 106
    Aberdeen, SD 57401
    Main: 605-622-8700
  • Avera Cancer Institute — Pierre
    801 E Sioux Ave
    Pierre, SD 57501
    Main: 605-224-3370